Literature DB >> 9164414

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.

Z Hussein1, J Eaves, D B Hutchinson, C J Canfield.   

Abstract

The population pharmacokinetics of atovaquone were examined in 458 black, Oriental, and Malay patients with acute Plasmodium falciparum malaria receiving atovaquone alone or concomitantly with other drugs. Oral clearance (CL/F) showed a 0.674 power relationship with weight and is similar in Oriental and Malay subjects but 58.5% lower in black subjects. On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively. The relationship between apparent volume of distribution (V area/F) and weight was linear and similar in all three races at 7.98 L/kg. The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively. The bioavailability of the high and low doses of atovaquone was similar. Neither CL/F nor V area/F were significantly affected by age, gender, and the coadministration with chloroguanide (proguanil), pyrimethamine, and tetracycline. Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively. The final magnitudes of interpatient variability in CL/F and V area/F were 68% and 49%, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164414     DOI: 10.1016/S0009-9236(97)90132-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.

Authors:  M D Edstein; B M Kotecka; K L Anderson; D J Pombo; D E Kyle; K H Rieckmann; M F Good
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

5.  Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Authors:  F Ezzet; M van Vugt; F Nosten; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

7.  Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports.

Authors:  Gilles Cottrell; Lise Musset; Véronique Hubert; Jacques Le Bras; Jérôme Clain
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

9.  Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.

Authors:  Iftekhar Mahmood; Anna Cheng; Edward Brauer; Rita Humeniuk
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

10.  The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.

Authors:  R McGready; K Stepniewska; M D Edstein; T Cho; G Gilveray; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.